Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
10.1007/s13238-020-00789-5
- Author:
Pranavi KOPPULA
1
;
Li ZHUANG
1
;
Boyi GAN
2
Author Information
1. Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
2. Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bgan@mdanderson.org.
- Publication Type:Review
- Keywords:
SLC7A11;
cancer therapy;
cysteine;
cystine;
ferroptosis;
nutrient dependency;
xCT
- From:
Protein & Cell
2021;12(8):599-620
- CountryChina
- Language:English
-
Abstract:
The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to import cystine for glutathione biosynthesis and antioxidant defense and is overexpressed in multiple human cancers. Recent studies revealed that SLC7A11 overexpression promotes tumor growth partly through suppressing ferroptosis, a form of regulated cell death induced by excessive lipid peroxidation. However, cancer cells with high expression of SLC7A11 (SLC7A11
